NCT05712889View on ClinicalTrials.gov

Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

January 24, 2023

Primary Completion Date

October 10, 2024

Study Completion Date

October 10, 2024

Conditions
Neoplasms
Interventions
DRUG

VIP236 (Q3W)

VIP236 will be administered by IV infusion once every 3 weeks, for a 21-day cycle.

DRUG

VIP236 (Q2W)

VIP236 will be administered by IV infusion once every 2 weeks, for a 28-day cycle.

Trial Locations (6)

2109

Macquarie University, Macquarie Park

4101

ICON Brisbane, Brisbane

5037

ICON Adelaide, Adelaide

78229

NEXT Oncology San Antonio, San Antonio

78758

NEXT Austin, Austin

85258

Honor Health, Scottsdale

All Listed Sponsors
lead

Vincerx Pharma, Inc.

INDUSTRY